PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

02 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

16 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

09 Sep 2024 07:00:47 By Nasdaq GlobeNewswire

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

01 Aug 2024 06:45:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

31 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at BTIG Virtual Biotechnology Conference

29 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

12 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

15 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

09 May 2024 16:46:46 By Nasdaq GlobeNewswire

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Details of Virtual KOL Event

03 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire